Impact of a Transmission Checklist in Post Anesthesia Care Unit on Immediate Respiratory Complications (TC-IRC)

November 9, 2020 updated by: Ramsay Générale de Santé
This work highlighted the beneficial role in terms of carers' satisfaction, quantity and quality of information transmitted.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Communication and information transmission problems are responsible for the majority of serious adverse events. The use of a checklist in the operating theatre has demonstrated its benefit in terms of reducing morbidity and mortality Regarding transmissions between caregivers, numerous studies have shown the great difference between the medical data of a patient in their file and the information transmitted.

The authors recommend using checklists in order to standardise transmissions. This work highlighted the beneficial role in terms of carers' satisfaction, quantity and quality of information transmitted. On the other hand, no study has looked at the reduction of immediate postoperative complications in post anaesthesia care units (PACU).

Study Type

Observational

Enrollment (Actual)

560

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • IDF
      • Versailles, IDF, France, 78000
        • Les Franciscaines Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

adult patients admitted to PACU

Description

Inclusion Criteria:

  • Male or Female over 18 admitted to PACU

  • Patient having understood the aims and the methods of the research

    • Patient having expressed their consent to the use of their data.
    • Subject registered with or beneficiary of a social security scheme

Exclusion Criteria:

  • Patient participating in another clinical study
  • Acute or chronic respiratory insufficiency preoperatively
  • Protected patient: adult under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision
  • Pregnant or lactating women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
IRCTC group
- The IRCTC group, consisting of all patients included in the 3rd phase of the study and for whom the transmission of information in PACU is carried out using the IRCTC.
Other: With or wiyhout a checklist
The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
CONTROL group
- The CONTROL group, consisting of all patients included in the 1st phase of the study and for whom the transmission of information in PACU is carried out according to the usual practice.
Other: With or wiyhout a checklist
The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
arterial oxygen desaturation < 90%
Time Frame: event of at least 15 second duration
The primary endpoint is defined as the occurrence or not of arterial oxygen desaturation < 90% for more than 15 consecutive seconds in PACU.
event of at least 15 second duration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ramsay Générale de Santé

Collaborators

Dr. Frédéric MARTIN

Investigators

  • Principal Investigator: Frederic Martin, Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 18, 2019

Primary Completion (Actual)

February 18, 2019

Study Completion (Actual)

July 7, 2020

Study Registration Dates

First Submitted

May 26, 2019

First Submitted That Met QC Criteria

May 31, 2019

First Posted (Actual)

June 3, 2019

Study Record Updates

Last Update Posted (Actual)

November 12, 2020

Last Update Submitted That Met QC Criteria

November 9, 2020

Last Verified

May 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ID-RCB : 2018-A01825-50

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Complications

Clinical Trials on With or wiyhout a checklist

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe